Life sciences software & AI news

Daily news on AI, software, and digital tools for pharma, biotech, CROs, and life sciences research labs.

Showing 1000+ results
Press release cover image

Nov 5, 2026

Press release

Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition

Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3 trial-in-progress design as site activation advances, first patient dosing remains on track for 1Q 2027 and FDA filing for accelerated approval remains targeted for 1H27 FLORHAM PARK, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical compa
Press release cover image

Nov 5, 2026

Press release

Climb Bio to Present New Data for Budoprutug in Immune Thrombocytopenia at the 68th American Society of Hematology Annual Meeting and Exposition

WELLESLEY HILLS, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for budoprutug in immune thrombocytopenia (ITP) at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, which will be held in New Orleans, Louisiana from December 12-15, 2026. Climb Bio will present data, including safety,
Press release cover image

Nov 5, 2026

Press release

Damora Therapeutics to Present New Preclinical Data Highlighting Potentially Best-in-Class Pan-Mutant Activity of DMR-001 in Mutant Calreticulin (mutCALR)-driven Myeloproliferative Neoplasms (MPN) at the American Society of Hematology (ASH) 2026 Annual Meeting

-- Building on previously presented DMR-001 preclinical data in Type 1 and Type 2 CALR mutations,new data to highlight strong activity against additional non-Type 1 mutations -- -- Trial-in-progress presentation to highlight the ongoing CLARITY-101 Phase 1/1b trial of DMR-001 in mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF) -- WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefi
Press release cover image

Nov 5, 2026

Press release

Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026

New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatmentUpdated data to be presented from first-in-human trial of LB2501, an investigational, off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells BRIDGEWATER, N.J., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that multiple abstracts were
Press release cover image

Nov 5, 2026

Press release

Kamau Therapeutics Announces First Multi-Patient Clinical Data Showing Precise Correction of the Sickle Cell Mutation and Restoration of Adult Hemoglobin

All three patients are transfusion-independent with no vaso-occlusive events; predominant adult hemoglobin profile restored, with sickle hemoglobin below 20% beyond six months Data to be featured in an oral presentation at the 68th ASH Annual Meeting on December 14, 2026 SAN FRANCISCO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Kamau Therapeutics, a clinical-stage company creating medicines that endure by precisely engineering patients’ own blood stem cells, today announced that new clinical data, inclu
Press release cover image

Nov 4, 2026

Press release

Laza Medical Raises Up to $160 Million in Series B Financing Led by GE HealthCare to Advance Intelligent Imaging for Transforming the Cath Lab

Company's first-of-a-kind intelligent imaging system aims to expand patient access, streamline high-quality cardiac care, and establish the foundation for future robotic interventionsLOS GATOS, Calif., Nov. 4, 2026 /PRNewswire/ -- Laza Medical, Inc., a Shifamed portfolio company pioneering AI-powered robotic imaging solutions for cardiac interventions, today announced it has raised up to $160 million in Series B structured financing. GE HealthCare led the round, with participation from returning
A custom DNA strand on a lab bench with a pipette nearby.

Nov 4, 2026

Building Custom DNA without Bacterial Constraints

Ribbon Bio is revolutionizing DNA assembly by eliminating the reliance on bacterial hosts, addressing significant challenges faced by molecular biologists.Traditionally, constructing custom DNA sequences involves inserting them into bacteria, a method that has been the cornerstone of molecular biology for decades. However, this approach is often slow, requires extensive infrastructure, and can fail with certain sequences that bacteria struggle to maintain. Ribbon Bio's innovative cell-free assem
Press release cover image

Nov 4, 2026

Press release

New Research Suggests hERG IC₁₀ May Improve Prediction of Drug-Induced QT Prolongation

NEW ORLEANS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Dr. William J. Crumb Jr., Ph.D., President and CEO of Nova Research Laboratories, LLC, has collaborated with Dr. Andrew G. Edwards, Ph.D., Chief Research Scientist of Simula Research Laboratory in Oslo, Norway and COO of Organos in Berkely, California, on a new publication titled “Predicting thorough QT safety profile using hERG IC10 versus IC50.” Published in the Journal of Pharmacological and Toxicological Methods, the study examines an alternat
Press release cover image

Nov 4, 2026

Press release

Therap Services Enhances Person-Centered Care with Secure Video Documentation

TORRINGTON, Conn., Nov. 4, 2026 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic documentation solutions for Intellectual and Developmental Disabilities (IDD), Home and Community-Based Services (HCBS), and Long-Term Services, offers Secure Video Documentation, a HIPAA-compliant tool that enables service providers to incorporate video into their existing workflows and capture additional visual context to support person-centered care.Designed specifically for serv
A blood pressure cuff and patient chart in a dimly lit examination room.

Nov 4, 2026

ARCare triples nurse capacity by combining RPM and chronic care management

ARCare has significantly enhanced its nurse capacity by integrating remote patient monitoring (RPM) with chronic care management (CCM), allowing for a more holistic approach to patient care.At ARCare, a federally qualified health center serving multiple states, the integration of RPM and CCM arose from the need to address fragmented care management. Previously, separate teams managed RPM and CCM, leading to gaps in understanding the complete patient picture. By combining these efforts, nurses ca
Minimalist illustration of an HVAC system in a biomanufacturing facility

Nov 4, 2026

Greener Biomanufacturing Starts Beyond the Bioreactor

A recent study highlights that the energy consumption in monoclonal antibody production is largely influenced by facility infrastructure rather than just bioreactor technology.Research indicates that around 85% of the energy demand in antibody manufacturing is attributed to the facility's infrastructure, including HVAC systems, lighting, and utilities. Specifically, HVAC systems alone account for nearly half of the total energy use, with lighting contributing significantly as well. This suggests
Press release cover image

Nov 4, 2026

Press release

MyOme and SickKids Collaborate to Clinically Validate DNA Methylation Signatures Using Long-Read Sequencing

MyOme Licenses SickKids-Developed DNA Methylation Signatures to Strengthen Long-Read Rare Disease Testing.MENLO PARK, Calif., Nov. 4, 2026 /PRNewswire/ -- MyOme, a CLIA-certified, CAP-accredited clinical whole-genome analysis company, today announced a licensing and research agreement with The Hospital for Sick Children (SickKids) through its Industry Partnerships & Commercialization (IP&C) team under which MyOme will integrate DNA methylation signatures developed by SickKids researchers